Publications by authors named "Todd Correll"

Claim this Profile
A
A Phase 2 Trial of Tobevibart plus Elebsiran in Hepatitis D.
Tarik Asselah, Michael A Chattergoon, Alina Jucov, Anca Streinu-Cercel, Pietro Lampertico, Todd Correll

N Engl J Med· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy and safety of doravirine/islatravir in heavily treatment-experienced participants living with HIV-1 from a randomized trial.
Andrew Carr, Rosie Mngqibisa, Ilsiyar Khaertynova, Princy N Kumar, Shariq Haider, Todd Correll

AIDS· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Doravirine/Islatravir (100/0.75 mg) Once-Daily Compared With Bictegravir/Emtricitabine/Tenofovir Alafenamide as Initial HIV-1 Treatment: 48-Week Results From a Phase 3, Randomized, Controlled, Double-Blind, Noninferiority Trial.
Jürgen K Rockstroh, Roger Paredes, Pedro Cahn, Jean-Michel Molina, Simiso M Sokhela, Todd Correll

Clin Infect Dis· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Switch to fixed-dose doravirine (100 mg) with islatravir (0·75 mg) once daily in virologically suppressed adults with HIV-1 on antiretroviral therapy: 48-week results of a phase 3, randomised, open-label, non-inferiority trial.
Jean-Michel Molina, Giuliano Rizzardini, Catherine Orrell, Alejandro Afani, Alexandra Calmy, Todd A Correll

Lancet HIV· June 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Switch to fixed-dose doravirine (100 mg) with islatravir (0·75 mg) once daily in virologically suppressed adults with HIV-1 on bictegravir, emtricitabine, and tenofovir alafenamide: 48-week results of a phase 3, randomised, controlled, double-blind, non-inferiority trial.
Anthony M Mills, Giuliano Rizzardini, Moti N Ramgopal, Olayemi O Osiyemi, Johannes R Bogner, Todd Correll

Lancet HIV· June 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Brief Report: Efficacy and Safety of Oral Islatravir Once Daily in Combination With Doravirine Through 96 Weeks for Treatment-Naive Adults With HIV-1 Infection Receiving Initial Treatment With Islatravir, Doravirine, and Lamivudine.
Jean-Michel Molina, Yazdan Yazdanpanah, Alejandro Afani Saud, Christopher Bettacchi, Carolina Chahin Anania, Todd Correll

J Acquir Immune Defic Syndr· September 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Islatravir in combination with doravirine for treatment-naive adults with HIV-1 infection receiving initial treatment with islatravir, doravirine, and lamivudine: a phase 2b, randomised, double-blind, dose-ranging trial.
Jean-Michel Molina, Yazdan Yazdanpanah, Alejandro Afani Saud, Christopher Bettacchi, Carolina Chahin Anania, Todd Correll

Lancet HIV· June 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety and Efficacy of Atazanavir Powder and Ritonavir in HIV-1-Infected Infants and Children From 3 Months to <11 Years of Age: The PRINCE-2 Study.
Mark F Cotton, Afaaf Liberty, Indiana Torres-Escobar, Maria Isabel Gonzalez-Tome, Jurgen Lissens, Todd A Correll

Pediatr Infect Dis J· June 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pharmacokinetics and Pharmacodynamics of Atazanavir in HIV-1-Infected Children Treated With Atazanavir Powder and Ritonavir: Combined Analysis of the PRINCE-1 and -2 Studies.
Heather Sevinsky, Luna Zaru, Reena Wang, Xiaohui Xu, Cheryl Pikora, Todd A Correll

Pediatr Infect Dis J· June 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
PRINCE-1: safety and efficacy of atazanavir powder and ritonavir liquid in HIV-1-infected antiretroviral-naïve and -experienced infants and children aged ≥3 months to <6 years.
Renate Strehlau, Anamaria Pena Donati, Pedro Martinez Arce, Jurgen Lissens, Rong Yang, Todd Correll

J Int AIDS Soc· May 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cost-effectiveness of efavirenz vs rilpivirine in HIV patients initiating first-line combination antiretroviral therapy.
Machaon Bonafede, Timothy Juday, Greg Lenhart, Katy Pan, Tony Hebden, Todd Correll

J Med Econ· September 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cost-effectiveness of the once-daily efavirenz/emtricitabine/tenofovir tablet compared with the once-daily elvitegravir/cobicistat/emtricitabine/tenofovir tablet as first-line antiretroviral therapy in HIV-infected adults in the US.
Timothy Juday, Todd Correll, Ayanna Anene, Michael S Broder, Jesse Ortendahl

Clinicoecon Outcomes Res· September 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effect of persistency of first-line HIV antiretroviral therapy on clinical outcomes.
James H Willig, Andrew O Westfall, Michael Mugavero, Christa R Nevin, Todd Correll

AIDS Res Hum Retroviruses· April 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Adherence and persistence with non-nucleoside reverse transcriptase inhibitor-based antiretroviral regimens.
Charu Taneja, Timothy Juday, Larry Gertzog, John Edelsberg, Todd Correll

Expert Opin Pharmacother· October 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Frequency of HIV-related medication errors and associated risk factors in hospitalized patients.
Sonak D Pastakia, Amanda H Corbett, Ralph H Raasch, Sonia Napravnik, Todd A Correll

Ann Pharmacother· April 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Integrase inhibitors: a new treatment option for patients with human immunodeficiency virus infection.
Todd Correll, Olga M Klibanov

Pharmacotherapy· January 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Treatment of zygomycosis with posaconazole in a patient with acute myeloid leukemia.
Helen L Leather, Todd A Correll, Christine L Meyer, Ilona M Schmalfuss, John R Wingard

Clin Adv Hematol Oncol· October 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis